Oesophageal Dopper Monitoring (ODM) company Deltex Medical is adding non-invasive high definition Impedance Cardiography (HD-ICG) module to its platform.
Background
Deltex Medical Group plc, is the global leader in Oesophageal Doppler Monitoring (ODM), a technology that allows clinicians to guide fluid and drug administration during major and high risk surgery. Now the company is adding a new string to its bow by launching a non-invasive High Definition Impedance Cardiography (HD-ICG) module to its CardioQ-ODM+ monitoring platform. The clear intention is to offer a suite including all three leading haemodynamic monitoring technologies, this addition following that of Pulse Pressure Waveform Analysis to CardioQ-ODM+ back in 2012. In effect, adding HD-ICG will increase the numbers of patients for whom Deltex monitoring is appropriate.
Complementary to ODM, HD-ICG is another way of providing a continuous indirect measurement of central blood flow. Disposable sensors are placed across the patient’s abdomen and an electrical field is set up across the chest. The system measures disruption to this field caused by the heart pumping blood, using this to calculate cardiac output variables using an established nomogram. The sensors are connected to the Deltex monitor via a small console which also powers the sensors and values are displayed on specially designed screens on the CardioQ-ODM+.
The HD-ICG system is non-invasive making it ideal for monitoring patients in both critical care and surgery who are awake and do not tolerate ODM probes.
The new product is CE marked and will be launched immediately in the UK and Deltex says it plans to launch in select overseas markets over the course of 2017.
The software upgrade necessary to add the new product to the US version of the CardioQ-ODM+ requires separate regulatory clearance which the Company is pursuing with the manufacturer’s support.
Company comments
Deltex Medical’s Chief Executive, Ewan Phillips commented: “The addition of High Definition Impedance Cardiography to our monitoring platform is an exciting development. It gives us an easy-to-use non-invasive cardiac output monitoring technology which is broadly complementary to our existing ODM technology.
“(By offering) all three of the leading advanced haemodynamic monitoring technologies on a single platform, clinicians can choose the most appropriate technology for their monitoring requirements across the whole hospital.”
Source: Deltex Medical plc
published: May 26, 2017 in: Launches / Withdrawals, Monitoring, Technology